Company intelligence / Profile preview

CerFlux

Birmingham, Alabama, United Statescerflux.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CerFlux has developed and patented the POET® and ChipMux® platforms, which enable rapid, ex vivo testing of multiple anticancer drugs directly on patient tumor biopsy tissue. This approach aims to identify the most effective treatment for each individual before therapy begins, reducing exposure to ineffective treatments. The technology is being validated in partnership with leading academic centers such as the James Comprehensive Cancer Center at Ohio State University[2][5]. No direct clinical trial results are published yet; focus is on platform validation and implementation.

Therapeutic areas: Oncology
Modalities: Device (biopsy-on-a-chip)Ex vivo assay technology
Industry: Molecular Diagnostics

Partnerships

James Comprehensive Cancer Center at Ohio State University[2][3][5]

Beyond the preview

Go deeper on CerFlux.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CerFlux.

Explore the full profile